Evaluation of Genomic Applications in Practice and Prevention (EGAPP) is an initiative launched in 2004 to support a coordinated, systematic process for evaluating genetic tests and other genomic applications that are in transition from research to clinical and public health practice in the United States.

 

The EGAPP Working Group was established in 2005 to support the development of a systematic process for assessing the available evidence regarding the validity and utility of rapidly emerging genetic tests for clinical practice.  This independent, multidisciplinary panel prioritizes and selects tests, reviews CDC-commissioned evidence reports and other contextual factors, highlights critical knowledge gaps, and provides guidance on appropriate use of genetic tests in specific clinical scenarios.

 

 

What's New

 

EGAPP Initiative Seeks Nominations for Working Group

The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative is seeking nominations for qualified individuals to serve on the EGAPP Working Group. Read more.

 

 

EGAPP Working Group announces the release of a commissioned Evidence Report

The independent Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group, supported by the Office of Public Health Genomics at the (CDC), announces the release of a commissioned Agency for Healthcare Research and Quality (AHRQ) evidence report entitled: Outcomes of Genetic Testing in Adults with a History of Venous Thromboembolism. (PDF 681KB) The EGAPP Working Group will be using this report as a basis for their deliberations for a recommendation.

 

You are invited to respond to a survey on the Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative.  Click here to complete the survey.

 

 

EGAPP Working Group Releases Three New Genetic Testing Recommendations

The independent Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group, supported by the Office of Public Health Genomics at the (CDC), has released new evidence-based recommendations on the validity and utility of three genetic tests currently being used in clinical practice. The new recommendation statements address the following:

 

 

EGAPP Working Group Methods Published

The independent EGAPP Working Group has developed new approaches and optimized existing methods for collecting, analyzing and grading evidence on analytic and clinical validity and clinical utility of genetic and genomic tests. These methods are described in an article in Genetics in Medicine.   (PDF466KB)   Learn more about the EGAPP Process and CDC’s EGAPP Initiative.

 

 

Evidence Reports

 

• Outcomes of Genetic Testing in Adults with a History of Venous Thromboembolism
  The Johns Hopkins University Evidence Based Practice Center | June 2009

 

• EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome.  (PDF 664KB) CDC/OPHG in collaboration with IPMMS | January 2009

 

• Can UGT1A1 Genotyping Reduce Morbidity and Mortality in Patients with Metastatic Colorectal Cancer Treated with Irinotecan?   (PDF 502KB) CDC, in conjunction with IPMMS and RTI I January 2009

 

• Impact of Gene Expression Profiling Tests on Breast Cancer Outcomes
  The Johns Hopkins University Evidence Based Practice Center | January 2008

 

• Hereditary Nonpolyposis Colorectal Cancer: Diagnostic Strategies and Their Implications
  Tufts New England Medical Center Evidence Based Practice Center | May 2007

 

• Testing for Cytochrome P450 Polymorphisms (CYP450) in Adults with Non-Psychotic Depression Prior to Treatment with Selective Serotonin Reuptake Inhibitors (SSRIs)
  Duke University AHRQ Evidence-based Practice Center | January 2007

 

Meetings

 

• Working Group Meeting, February 1st - February 2nd, 2010
  Location: Horton Grand Hotel, San Diego, California
  Announcement | Agenda

 

Home | About EGAPP | Understanding EGAPP | Working Group | Meetings | Topics | Methods | Evidence Reports | Recommendations | Contact Us
© 2009 Evaluation of Genomic Applications in Practice and Prevention (EGAPP)